Arvinas Will Present Parkinson's Drug Data in October
The company will share early-stage research on a new protein-targeting therapy for brain-related conditions.
Updated on Oct. 1, 2026 in Alzheimer’s
Arvinas is set to present Phase 1 clinical trial results for its investigational drug, ARV-102, during the 2026 International Congress of Parkinson's Disease and Movement Disorders. The findings will be shared with the medical community in Seoul from October 4-8, 2026.
Why it matters
As a potential treatment for Parkinson's disease and progressive supranuclear palsy, this drug represents a new approach to addressing proteins implicated in neurodegeneration. Understanding these initial study results is a step toward determining if this therapy could eventually impact future treatment options.
Researchers conducted a Phase 1 clinical trial to evaluate the safety and biomarker impact of ARV-102 in an initial study population. These preliminary results provide the first data on the drug's performance in humans.
The players
Arvinas
A biopharmaceutical company based in New Haven, Connecticut, specializing in protein degradation technology for neurodegenerative and oncological conditions.
The details
ARV-102 is designed as a PROTAC LRRK2 degrader that specifically targets the LRRK2 protein, which is linked to the development of Parkinson's disease and progressive supranuclear palsy. The drug is engineered to cross the blood-brain barrier, a critical challenge for therapies intended to treat neurological conditions. By degrading this protein, the treatment aims to modulate the underlying biological drivers of these disorders.
Timeline
October 4-8, 2026: The International Congress of Parkinson's Disease and Movement Disorders takes place in Seoul.
October 7, 2026: Arvinas will deliver an oral presentation of the ARV-102 study data.
Health Landscape
This research contributes to the expanding field of targeted protein degradation, an approach that is moving from laboratory investigation into clinical evaluation. It represents a shift in neurodegenerative care as scientists attempt to treat conditions by directly addressing implicated protein levels.
While these preliminary findings provide insight into the drug's mechanism, they do not yet change current treatment standards for patients. Any questions regarding the availability of new clinical trials or experimental options should be discussed with a neurologist or specialist.
The takeaway
The development of LRRK2 degraders marks a growing focus on protein regulation in the brain. Patients and caregivers should continue to track progress in neurology through established medical organizations and consult with their physician about currently available, evidence-based care options.
Further reading
For more information on the latest research and clinical developments for neurodegenerative conditions, visit our Alzheimer’s section.
